Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
- Conditions
- Neoplasm
- Interventions
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 33
- Registration Number
- NCT05450562
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center- Site Number : 8400004, Los Angeles, California, United States
🇺🇸Icahn School of Medicine at Mount Sinai- Site Number : 8400005, New York, New York, United States
🇺🇸Lifespan Corporation- Site Number : 8400002, Providence, Rhode Island, United States
A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 80
- Registration Number
- NCT05442645
- Locations
- 🇨🇳
Investigational site-National Taiwan University Hospital, Taipei, Taiwan, China
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT05429762
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center Site Number : 8400002, Dallas, Texas, United States
🇪🇸Investigational Site Number : 7240002, Barcelona, Catalunya [Cataluña], Spain
🇹🇷Investigational Site Number : 7920001, Ankara, Turkey
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 446
- Registration Number
- NCT05421598
- Locations
- 🇨🇦
Investigational Site Number : 1240003, Quebec, Canada
🇨🇦Investigational Site Number : 1240007, Trois-Rivieres, Quebec, Canada
🇺🇸Treasure Valley Medical Research Site Number : 8400031, Boise, Idaho, United States
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 582
- Registration Number
- NCT05413369
- Locations
- 🇨🇳
Investigational Site Number : 1560025, Harbin, China
🇨🇳Investigational Site Number : 1560008, Baotou, China
🇨🇳Investigational Site Number : 1560001, Beijing, China
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
- Conditions
- Plasma Cell Myeloma Recurrent
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 531
- Registration Number
- NCT05405166
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL- Site Number : 8400015, Prescott Valley, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, LLP- Site Number : 8400021, Aurora, Colorado, United States
🇺🇸Mayo Clinic- Site Number : 8400008, Jacksonville, Florida, United States
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above
- Conditions
- Influenza
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 675
- Registration Number
- NCT05406180
- Locations
- 🇰🇷
Site 012, Gwangju, Korea, Republic of
🇰🇷Site 004, Incheon, Korea, Republic of
🇰🇷Site 007, Incheon, Korea, Republic of
First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 36
- Registration Number
- NCT05366764
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
🇬🇧Investigational Site Number : 8260001, Belfast, United Kingdom
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT05359276
- Locations
- 🇫🇷
Investigational site in France, France, France
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 49
- Registration Number
- NCT05326412
- Locations
- 🇩🇪
Investigational Site Number : 2760004, Peine, Germany
🇺🇸Harvard Medical School - Massachusetts General Hospital (MGH) - Medical Practice Evaluation Center (MPEC)- Site Number : 8400007, Boston, Massachusetts, United States
🇺🇸University of Kansas Medical Center- Site Number : 8400004, Kansas City, Missouri, United States